ATE397458T1 - Neue heilmittel für krebs - Google Patents
Neue heilmittel für krebsInfo
- Publication number
- ATE397458T1 ATE397458T1 AT01954360T AT01954360T ATE397458T1 AT E397458 T1 ATE397458 T1 AT E397458T1 AT 01954360 T AT01954360 T AT 01954360T AT 01954360 T AT01954360 T AT 01954360T AT E397458 T1 ATE397458 T1 AT E397458T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- new cure
- cure
- new
- medicament
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 abstract 1
- 229960002550 amrubicin Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000228239 | 2000-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397458T1 true ATE397458T1 (de) | 2008-06-15 |
Family
ID=18721568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01954360T ATE397458T1 (de) | 2000-07-28 | 2001-07-26 | Neue heilmittel für krebs |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7449181B2 (de) |
| EP (1) | EP1308168B1 (de) |
| JP (1) | JP5117660B2 (de) |
| KR (1) | KR20030019623A (de) |
| CN (2) | CN101732333B (de) |
| AT (1) | ATE397458T1 (de) |
| AU (1) | AU2001276689A1 (de) |
| CA (1) | CA2417255C (de) |
| DE (1) | DE60134324D1 (de) |
| DK (1) | DK1308168T3 (de) |
| ES (1) | ES2307633T3 (de) |
| TW (1) | TWI317285B (de) |
| WO (1) | WO2002009754A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| CN1447696A (zh) * | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| ATE545423T1 (de) | 2002-03-18 | 2012-03-15 | Dainippon Sumitomo Pharma Co | Mittel zur behandlung von lungenkrebs |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| CA2583230A1 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
| CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
| CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| MX2007009889A (es) | 2005-02-23 | 2007-09-07 | Genentech Inc | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer. |
| TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| ES2477497T3 (es) | 2007-03-02 | 2014-07-17 | Genentech, Inc. | Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo |
| CA3006428A1 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| CN102753193A (zh) | 2008-10-31 | 2012-10-24 | 比奥根艾迪克Ma公司 | Light靶向分子及其用途 |
| AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
| SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| SG183333A1 (en) | 2010-02-18 | 2012-09-27 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| EP2785864A2 (de) | 2011-11-30 | 2014-10-08 | F. Hoffmann-La Roche AG | Erbb3-mutationen bei krebs |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| CA2865082A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6075473A (ja) * | 1983-09-30 | 1985-04-27 | Sumitomo Chem Co Ltd | アミノナフタセン誘導体 |
| US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5077220A (en) * | 1988-08-26 | 1991-12-31 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells |
| JPH035397A (ja) | 1989-05-31 | 1991-01-11 | Toshiba Corp | 酸化物結晶薄膜の気相成長方法 |
| JP3005397B2 (ja) | 1993-09-06 | 2000-01-31 | 関西日本電気ソフトウェア株式会社 | デッドロック多発自動回避方式 |
| US5686278A (en) * | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
| CN1164238A (zh) * | 1994-09-12 | 1997-11-05 | 国际生物免疫有限公司 | 抗人结肠癌相关抗原的单克隆抗体及其应用 |
| KR19990082463A (ko) * | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| CN1082187C (zh) * | 1996-11-26 | 2002-04-03 | 北京市肿瘤防治研究所 | 一种检测雌激素受体水平的生物试剂及免疫组化方法 |
| EP0988056B1 (de) * | 1997-01-22 | 2003-07-09 | Board Of Regents, The University Of Texas System | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren |
| US20030068318A1 (en) * | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
-
2001
- 2001-07-24 TW TW90118039A patent/TWI317285B/zh not_active IP Right Cessation
- 2001-07-26 EP EP20010954360 patent/EP1308168B1/de not_active Expired - Lifetime
- 2001-07-26 KR KR10-2003-7001194A patent/KR20030019623A/ko not_active Withdrawn
- 2001-07-26 CA CA 2417255 patent/CA2417255C/en not_active Expired - Fee Related
- 2001-07-26 DK DK01954360T patent/DK1308168T3/da active
- 2001-07-26 AU AU2001276689A patent/AU2001276689A1/en not_active Abandoned
- 2001-07-26 DE DE60134324T patent/DE60134324D1/de not_active Expired - Lifetime
- 2001-07-26 WO PCT/JP2001/006467 patent/WO2002009754A1/ja not_active Ceased
- 2001-07-26 CN CN2009102523811A patent/CN101732333B/zh not_active Expired - Fee Related
- 2001-07-26 JP JP2002501211A patent/JP5117660B2/ja not_active Expired - Lifetime
- 2001-07-26 US US10/333,978 patent/US7449181B2/en not_active Expired - Fee Related
- 2001-07-26 CN CN01816215A patent/CN100581585C/zh not_active Expired - Fee Related
- 2001-07-26 ES ES01954360T patent/ES2307633T3/es not_active Expired - Lifetime
- 2001-07-26 AT AT01954360T patent/ATE397458T1/de active
-
2007
- 2007-06-11 US US11/761,264 patent/US7879327B2/en not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/978,275 patent/US9139658B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI317285B (en) | 2009-11-21 |
| EP1308168A4 (de) | 2004-09-01 |
| CN100581585C (zh) | 2010-01-20 |
| US20110104160A1 (en) | 2011-05-05 |
| US7879327B2 (en) | 2011-02-01 |
| US20030157097A1 (en) | 2003-08-21 |
| ES2307633T3 (es) | 2008-12-01 |
| DE60134324D1 (de) | 2008-07-17 |
| US20080031881A1 (en) | 2008-02-07 |
| CN101732333B (zh) | 2012-08-15 |
| CA2417255C (en) | 2011-08-02 |
| WO2002009754A1 (en) | 2002-02-07 |
| EP1308168A1 (de) | 2003-05-07 |
| CA2417255A1 (en) | 2003-01-24 |
| EP1308168B1 (de) | 2008-06-04 |
| CN1466464A (zh) | 2004-01-07 |
| CN101732333A (zh) | 2010-06-16 |
| KR20030019623A (ko) | 2003-03-06 |
| AU2001276689A1 (en) | 2002-02-13 |
| DK1308168T3 (da) | 2008-07-28 |
| US7449181B2 (en) | 2008-11-11 |
| JP5117660B2 (ja) | 2013-01-16 |
| US9139658B2 (en) | 2015-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397458T1 (de) | Neue heilmittel für krebs | |
| PT1196172E (pt) | (s,s)-reboxetina para tratar a dor cronica | |
| DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
| MXPA03000905A (es) | Compuestos de poliamina ciclicos como tratamiento contra el cancer. | |
| AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
| BR0012196A (pt) | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado | |
| IT1317735B1 (it) | Sali di agenti antimicrobici. | |
| DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
| MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
| PT1244650E (pt) | Derivados arilaminas e sua aplicacao como agentes anti-telomerase | |
| GB0019283D0 (en) | Organic compounds | |
| CY1110329T1 (el) | Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743 | |
| MXPA03003632A (es) | Metodo para tratamiento de tumores usando terapia de combinacion. | |
| BRPI0418589A (pt) | composições farmacêuticas e métodos para tratamento por insulina | |
| DE60235287D1 (de) | Löslich gemachte topoisomerase-gifte | |
| GB0008305D0 (en) | Treatment of fungal infections | |
| EP1354896A4 (de) | Neuer monoklonaler antikörper | |
| EE200300129A (et) | Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine | |
| EE200300082A (et) | Farmatseutilne kompositsioon urineerimishäire raviks | |
| DE60315288D1 (de) | Cyanoguanidin prodrugs | |
| BR0115882A (pt) | Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária | |
| EE200200605A (et) | Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| ES1044983Y (es) | Aparato de termoestimulacion para tratamientos terapeuticos. | |
| ES1044082Y (es) | Valvula perfeccionada para colchonetas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1308168 Country of ref document: EP |